IceCure Medical (NASDAQ:ICCM) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of IceCure Medical (NASDAQ:ICCM) from a sell rating to a hold rating in a research note published on Saturday morning,Wall Street Zen reports.

ICCM has been the topic of several other reports. Maxim Group decreased their price target on shares of IceCure Medical from $90.00 to $30.00 and set a “buy” rating on the stock in a research note on Thursday, May 14th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IceCure Medical in a research note on Friday, July 17th. Finally, Zacks Research lowered shares of IceCure Medical from a “hold” rating to a “strong sell” rating in a report on Friday, August 14th. Three analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, IceCure Medical currently has a consensus rating of “Hold” and a consensus price target of $52.50.

IceCure Medical Stock Performance

Shares of NASDAQ ICCM opened at $2.23 on Friday. The stock has a market cap of $7.65 million, a price-to-earnings ratio of -0.26 and a beta of 0.45. IceCure Medical has a 1-year low of $2.12 and a 1-year high of $42.00. The stock’s 50-day moving average is $3.18 and its 200 day moving average is $7.97.

IceCure Medical (NASDAQ:ICCM) last released its earnings results on Tuesday, June 30th. The company reported ($1.60) earnings per share for the quarter. The firm had revenue of $0.91 million during the quarter. IceCure Medical had a negative return on equity of 174.26% and a negative net margin of 427.67%. On average, analysts forecast that IceCure Medical will post -4.61 EPS for the current fiscal year.

Institutional Trading of IceCure Medical

An institutional investor recently bought a new position in IceCure Medical stock. Virtu Financial LLC bought a new stake in shares of IceCure Medical Ltd. (NASDAQ:ICCM) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 64,524 shares of the company’s stock, valued at approximately $39,000. Virtu Financial LLC owned approximately 0.09% of IceCure Medical at the end of the most recent quarter. 0.62% of the stock is owned by institutional investors.

IceCure Medical Company Profile

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.